Search

Displaying results 2551 - 2560 of 10000 in total
  1. Drug

    Pimavanserin

    go.drugbank.com/drugs/DB05316
    ApprovedInvestigational

    [A232783] It was approved by the FDA in April 2016 for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis thanks to favorable results from a pivotal six-week, randomized … In fact, pimavanserin is the first antipsychotic drug without D<sub>2</sub> blocking activity.

  2. Drug

    Betahistine

    go.drugbank.com/drugs/DB06698
    ApprovedInvestigational

    It is currently marketed in Canada by various companies, including Teva Pharmaceuticals. … [A220333,L16403] Betahistine was first approved by the FDA in the 1970s but withdrawn within approximately 5 years due to a lack of evidence supporting its efficacy.

    Synonyms: N-methyl-2-pyridineethanamine, N-methyl-2-(2-pyridinyl)ethanamineProducts: BETAVERT N 8MG, BETAVERT N 16MG
  3. Drug

    Propafenone

    go.drugbank.com/drugs/DB01182
    ApprovedInvestigational

    An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity. The drug is generally well tolerated.

    Categories: Antiarrhythmics, Class I, Antiarrhythmics, Class IcProducts: PROPAFENON AL 150, PROPAFENON AL 300
  4. Drug

    Prednisone

    go.drugbank.com/drugs/DB00635
    ApprovedInvestigationalVet approved

    A synthetic anti-inflammatory glucocorticoid derived from [cortisone].[A187463] It is biologically inert and converted to [prednisolone] in the liver. … [L10502] Prednisone was granted FDA approval on 21 February 1955.[L10496]

  5. Drug

    Flecainide

    go.drugbank.com/drugs/DB01195
    ApprovedInvestigationalWithdrawn

    Flecainide is a Class I anti-arrhythmic agent like [encainide] and [propafenone]. … [A186880] Flecainide’s development began in 1966 and was first synthesized in 1972 as an attempt to generate new anesthetics.

    Categories: Antiarrhythmics, Class I, Antiarrhythmics, Class IcSynonyms: N-(2-Piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide
  6. Drug

    Ferrous ascorbate

    go.drugbank.com/drugs/DB14490
    ApprovedWithdrawn

    Synonyms: Iron(2+) L-ascorbate, L-Ascorbic acid, iron complexCategories: Compounds used in a research, industrial, or household setting
  7. Drug

    Vibegron

    go.drugbank.com/drugs/DB14895
    ApprovedInvestigational

    [L28305] Vibegron was first approved in Japan in September 2018 for the treatment of overactive bladder,[A226050] a condition associated with distressing symptoms of urge urinary incontinence, urgency, … On December 23, 2020, vibegron was approved for the same indication in adults. It is available as oral tablets under the market name GEMTESA.

  8. Drug

    Tazemetostat

    go.drugbank.com/drugs/DB12887
    ApprovedInvestigational

    [L11476] Tazemetostat was first named in literature as EPZ-6438.[A190363] Tazemetaostat was granted FDA approval on 23 January 2020.[L11476] … Tazemetostat is a methyltransferase inhibitor used to treat metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.

  9. Drug

    Fosdenopterin

    go.drugbank.com/drugs/DB16628
    Approved

    Molybdenum cofactor deficiency (MoCD) is an exceptionally rare autosomal recessive disorder resulting in a deficiency of three molybdenum-dependent enzymes: sulfite oxidase (SOX), xanthine dehydrogenase … In 2009 a recombinant, E. coli-produced cPMP was granted orphan drug designation by the FDA, becoming the first therapeutic option for patients with MoCD type A.

  10. Drug

    Elivaldogene autotemcel

    go.drugbank.com/drugs/DB16746
    Approved

    [A243691] ALDP is a key protein that normally breaks down fatty substances in the body called very long-chain fatty acids (VLCFAs). … It was approved by the European Commission in July 2021 under the market name Skysona, and was later withdrawn in November 2021 at the request of the marketing-authorization holder.